Microbio is pleased to announce a new distribution agreement with CzechGenetics, a leading distributor of molecular biology and genetic diagnostics based in the Czech Republic.
This strategic partnership marks a significant step forward in Microbio’s international expansion, allowing its innovative sepsis diagnostic technology to reach clinicians and laboratories across Central Europe. Under the agreement, CzechGenetics will become the exclusive distributor of InfectID™-BSI in the Czech Republic and Slovakia.
“We’re thrilled to partner with CzechGenetics,” said Paul Rainey, Distributor Manager at Microbio. “Their deep expertise in molecular diagnostics and strong regional network make them an ideal partner to bring our technology to healthcare professionals who need faster, more accurate tools to identify bloodstream infections and improve patient outcomes.”
CzechGenetics shares a commitment to delivering high-quality, scientifically validated products to clinical laboratories and research institutions. Their portfolio includes a wide range of diagnostic tools, making them a trusted name in the Czech Republic and surrounding regions.
“There are many Real-Time PCR microbiology kits suppliers, but Microbio is very special one,” said Jiri Pehlik, CEO, at CzechGenetics. “InfectIDTM-BSI is a game-changer in sepsis diagnostics and we are really proud to be part of this revolution, one that brings speed and sensitivity to diagnostics, where both are absolutely key.”
InfectID™-BSI is a rapid molecular diagnostic test that identifies 26 pathogens responsible for >94% of bloodstream infections resulting in sepsis. Leveraging DNA melt curve analysis, InfectID™-BSI detects pathogens directly from blood samples without the need for culture, delivering results in just three hours. This CE-marked assay empowers clinicians to begin targeted treatment sooner, improving outcomes and supporting antimicrobial stewardship.
This agreement with CzechGenetics represents an important milestone in the company’s global growth strategy.